Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
PLYMOUTH, Minn., Jan. 28, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York, NY.
Entellus Medical’s management is scheduled to present on Thursday, February 11, 2016 at 12:00pm ET. Interested parties can access the live audio webcast at http://www.entellusmedical.com. An archived presentation will be available on the website for 30 days.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients. The Entellus Medical platform of products provides physicians with solutions to aid in the diagnosis and treatment of patients suffering from chronic sinusitis. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis. For more information, please visit the Company's website at www.entellusmedical.com.
Carrie Mendivil 415-513-1283 [email protected]
